Insys Therapeutics (INSY) Stock Price Up 6%

Share on StockTwits

Shares of Insys Therapeutics Inc (NASDAQ:INSY) rose 6% during mid-day trading on Monday . The company traded as high as $4.43 and last traded at $4.39. Approximately 816,987 shares traded hands during mid-day trading, a decline of 29% from the average daily volume of 1,158,811 shares. The stock had previously closed at $4.14.

INSY has been the topic of a number of research analyst reports. ValuEngine lowered Insys Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 21st. Piper Jaffray Companies set a $4.00 price target on Insys Therapeutics and gave the stock a “sell” rating in a research note on Friday, March 8th. Janney Montgomery Scott reaffirmed a “buy” rating and issued a $11.00 price target on shares of Insys Therapeutics in a research note on Wednesday, December 19th. Cantor Fitzgerald initiated coverage on Insys Therapeutics in a research note on Tuesday, January 22nd. They issued an “overweight” rating and a $4.40 price target on the stock. Finally, Royal Bank of Canada lowered their price target on Insys Therapeutics from $9.00 to $7.00 and set an “outperform” rating on the stock in a research note on Friday, March 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $7.28.

The stock has a market capitalization of $317.65 million, a P/E ratio of -3.16 and a beta of 2.56.

Insys Therapeutics (NASDAQ:INSY) last announced its quarterly earnings data on Thursday, March 7th. The specialty pharmaceutical company reported ($0.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.08). Insys Therapeutics had a negative return on equity of 431.71% and a negative net margin of 151.79%. The company had revenue of $16.36 million for the quarter, compared to analysts’ expectations of $17.93 million. On average, equities research analysts expect that Insys Therapeutics Inc will post -1.55 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in INSY. ETF Managers Group LLC purchased a new position in Insys Therapeutics during the fourth quarter worth approximately $5,076,000. Norges Bank purchased a new position in Insys Therapeutics during the fourth quarter worth approximately $2,195,000. D. E. Shaw & Co. Inc. lifted its position in Insys Therapeutics by 158.6% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 512,444 shares of the specialty pharmaceutical company’s stock worth $1,793,000 after buying an additional 314,264 shares in the last quarter. Raging Capital Management LLC purchased a new position in Insys Therapeutics during the fourth quarter worth approximately $998,000. Finally, Millennium Management LLC lifted its position in Insys Therapeutics by 88.7% during the fourth quarter. Millennium Management LLC now owns 545,487 shares of the specialty pharmaceutical company’s stock worth $1,909,000 after buying an additional 256,474 shares in the last quarter. Hedge funds and other institutional investors own 15.17% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Insys Therapeutics (INSY) Stock Price Up 6%” was first published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/4231472/insys-therapeutics-insy-stock-price-up-6.html.

About Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.

See Also: Special Dividends

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SJW Group  Position Cut by Chatham Capital Group Inc.
SJW Group Position Cut by Chatham Capital Group Inc.
Talon Metals  Hits New 52-Week High at $0.16
Talon Metals Hits New 52-Week High at $0.16
Brokerages Set Nutrien Ltd  Price Target at $61.50
Brokerages Set Nutrien Ltd Price Target at $61.50
Bovis Homes Group  Earns Hold Rating from Peel Hunt
Bovis Homes Group Earns Hold Rating from Peel Hunt
Paypoint plc  Declares Dividend of GBX 21
Paypoint plc Declares Dividend of GBX 21
Telefonaktiebolaget LM Ericsson  Upgraded to Buy by Bank of America
Telefonaktiebolaget LM Ericsson Upgraded to Buy by Bank of America


© 2006-2019 Ticker Report